Kazia Therapeutics Annual Reports 2023

74 FINANCIAL REPORT NOTES TO THE FINANCIAL STATEMENTS CONTINUED 30 June 2023 2023 Tranche Grant date Expiry date Exercise price Balance at the start of the year Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year 1 07/08/2017 07/08/2022 $0.6700 15,500 - - (15,500) - 2 05/02/2018 05/02/2023 $0.7802 240,000 - - (240,000) - 3 13/11/2019 04/01/2024 $0.4925 1,200,000 - - - 1,200,000 4 13/01/2020 13/01/2025 $0.8812 200,000 - - (12,500) 187,500 5 09/11/2020 09/11/2024 $1.1320 1,200,000 - - - 1,200,000 6 09/11/2020 13/01/2025 $0.8812 800,000 - - (200,000) 600,000 7 04/01/2021 04/01/2025 $1.6900 200,000 - - (12,500) 187,500 8 09/09/2021 26/06/2026 $1.3650 100,000 - - - 100,000 9 16/11/2021 16/11/2025 $1.6900 1,000,000 - - (250,000) 750,000 10 16/11/2021 16/11/2025 $2.2400 1,500,000 - - (1,000,000) 500,000 11 16/11/2021 16/11/2026 $1.5600 800,000 - - - 800,000 12 01/02/2022 01/02/2027 $0.9400 800,000 - - - 800,000 13 01/02/2022 01/02/2027 $0.9400 500,000 - - (75,000) 425,000 14 24/05/2022 24/05/2027 $0.7800 100,000 - - - 100,000 15 03/03/2023 03/03/2027 $0.1500 - 3,930,000 - - 3,930,000 16 03/05/2023 03/05/2027 $0.1870 - 4,000,000 - - 4,000,000 8,655,500 7,930,000 - (1,805,500) 14,780,000 Weighted average exercise price $1.2826 $0.1785 $0.0000 $1.8977 $0.6292 At the end of the period the following outstanding options were vested and exercisable: • Options in tranche 1 - 2 expired during the year • Options in tranches 3 & 6 were vested and exercisable • Options in tranches 4, 5, 7 & 9 were vested and exercisable to 75%, apart from those in the above table which have expired • Options in tranches 8 were vested and exercisable to 50%, apart from those in the above table which have expired • Options in tranche 10 & 16 were vested and exercisable as to 33%, apart from those in the above table which have expired • Options in tranche 11, 12, 13 & 14 were vested and exercisable as to 25%, apart from those in the above table which have expired • Options in tranche 15 were unvested The weighted average remaining contractual life of options outstanding at 30 June 2023 is 2.995 years. Note 32. Share-based payments continued

RkJQdWJsaXNoZXIy MjE2NDg3